Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

× No keyword cloud information.

74 in total

Review 1. B cells: new ways to inhibit their function in rheumatoid arthritis.

Authors: Robert H Carter
Journal: Curr Rheumatol Rep Date: 2004-10 Impact factor: 4.592

Review 2. B cell signalling as therapeutic target.

Authors: R H Carter
Journal: Ann Rheum Dis Date: 2004-11 Impact factor: 19.103

3. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.

Authors: Efrat Dotan; Charu Aggarwal; Mitchell R Smith
Journal: P T Date: 2010-03

Review 4. The role of immune tolerance in preventing and treating arthritis.

Authors: Gijs Teklenburg; Salvatore Albani
Journal: Curr Rheumatol Rep Date: 2004-12 Impact factor: 4.592

5. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

Authors: Norihito Yazawa; Yasuhito Hamaguchi; Jonathan C Poe; Thomas F Tedder
Journal: Proc Natl Acad Sci U S A Date: 2005-10-10 Impact factor: 11.205

Review 6. [Autoantibodies and antibody-secreting cells].

Authors: F Hiepe; T Dörner
Journal: Z Rheumatol Date: 2005-09 Impact factor: 1.372

7. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).

Authors: M Voulgarelis; S Giannouli; A G Tzioufas; H M Moutsopoulos
Journal: Ann Rheum Dis Date: 2005-12-01 Impact factor: 19.103

8. Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors: R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal: J Clin Aesthet Dermatol Date: 2013-01

9. B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.

Authors: Ikuko Hayakawa; Thomas F Tedder; Yuan Zhuang
Journal: Immunology Date: 2007-04-30 Impact factor: 7.397

Review 10. Biologic Agents in the Treatment of Multicentric Castleman Disease.

Authors: Konstantinos Kapriniotis; Savvas Lampridis; Sofoklis Mitsos; Davide Patrini; David R Lawrence; Nikolaos Panagiotopoulos
Journal: Turk Thorac J Date: 2018-10-01